Dublin, Jan. 09, 2024 (GLOBE NEWSWIRE) -- The "Intravascular Ultrasound (IVUS) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Intravascular ...

WILMINGTON, DE / ACCESSWIRE / October 13, 2022 / Transparency Market Research Inc. - The products and solutions offered by players in the global intravascular ultrasound (IVUS) devices market are used ...

Prolific medtech investor Vensana Capital’s next move is now evident. Literally: Evident Vascular, a startup incubated by the investor, has now exited stealth with plans to introduce an intravascular ...

Advances in coronary imaging are needed to enable the early detection of plaque segments considered to be 'vulnerable' for causing clinical events. Pathological studies have contributed to our current ...

Evident Vascular, a company creating AI-enabled intravascular ultrasound technology, announced its launch today with $35 million in Series A financing. Vensana Capital led the round. The ...

-Next generation intravascular ultrasound catheter improves image quality and deliverability NATICK, Mass. -- The Boston Scientific Corporation has received U.S. Food and Drug Administration clearance ...

Serial studies using IVUS enable assessment of the progression or regression of coronary atherosclerosis by visualizing the occurrence of atheroma in the vessel wall. A previous study using IVUS ...

In patients with coronary artery disease who are being evaluated for percutaneous coronary intervention (PCI), procedures can be guided by fractional flow reserve (FFR) or intravascular ...

Randomized to optical coherence tomography (OCT) or intravascular ultrasound (IVUS) guidance, patients who underwent percutaneous coronary intervention (PCI) with contemporary stents showed a decrease ...

SAN JOSE, Calif.--(BUSINESS WIRE)--Evident Vascular, Inc., a medical technology company developing a best-in-class intravascular ultrasound (IVUS) platform powered by artificial intelligence, today ...

SAN DIEGO, CA—IVUS-guided implantation of drug-eluting stents results in lower rates of target vessel failure (TVF) by 1 year compared to angiography-guided procedures, according to results from a new ...